Diagnostic News and Research

RSS

Optical coherence tomography can distinguish between high and low risk pancreatic cysts

A team of researchers from four Boston-area institutions led by Nicusor Iftimia from Physical Sciences, Inc. has demonstrated for the first time that optical coherence tomography (OCT), a high resolution optical imaging technique that works by bouncing near-infrared laser light off biological tissue, can reliably distinguish between pancreatic cysts that are low-risk and high-risk for becoming malignant.

18 Aug 2011

FDA approves Zelboraf (vemurafenib) for advanced skin cancer

A new drug was approved for advanced skin cancer this Wednesday by U.S. regulators, offering the first new treatment for melanoma in 13 years.

18 Aug 2011

Neoprobe sells gamma detection device business to Devicor

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it completed the previously announced sale of its neoprobe GDS line of gamma detection device systems to Devicor Medical Products, Inc. for $30 million in upfront consideration, plus up to an additional $20 million in royalties based on Devicor's achievement of certain revenue milestones.

18 Aug 2011

Roche receives FDA approval for Zelboraf to treat BRAF mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test.

18 Aug 2011

Zelboraf receives FDA approval for treatment of metastatic melanoma

The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

17 Aug 2011

Health Canada grants medical device license to Gen-Probe's PROGENSA PCA3 assay

Gen-Probe announced today that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.

17 Aug 2011

PERCH study to look at current and likely future causes of childhood pneumonia

Pneumonia kills more children around the world than any other disease, but the last major effort to study the causes of childhood pneumonia across many countries was conducted in the 1980's. This week, a groundbreaking new study called the Pneumonia Etiology Research for Child Health (PERCH) study gets off the ground.

17 Aug 2011

Methodist, Philips partner to develop new imaging technology for infectious diseases

The Methodist Hospital Research Institute and Philips Healthcare are collaborating to develop new imaging technology that could be used to help identify the start -- and cause -- of an infectious disease epidemic.

From Philips Healthcare 17 Aug 2011

Study investigates autism spectrum disorder, sibling recurrence

The risk that an infant with an older sibling with autism also will develop the disorder, previously estimated at between 3 and 10 percent, is substantially higher at approximately 19 percent, a large, international, multi-site study led by researchers at the UC Davis MIND Institute has found.

16 Aug 2011

Concord Medical second quarter total net revenues increase 24.5% to $19.2 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced higher revenues, net income, and earnings per ADS for its unaudited consolidated financial results for the second quarter ended June 30, 2011 compared with the second quarter ended June 30, 2010.

16 Aug 2011

China Medical first fiscal quarter net revenues increase 27.4% to US$36.7 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, announced its unaudited financial results for the first fiscal quarter ended June 30, 2011 today.

16 Aug 2011

New insights into causes of rheumatoid arthritis

Scientists at Mount Sinai Hospital, in collaboration with researchers at the University of Toronto, University Health Network and McGill University have obtained significant new insights into the causes of rheumatoid arthritis (RA) and other autoimmune disorders including type 1 diabetes, lupus and Graves disease.

16 Aug 2011

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

QIAGEN today announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer.

From QIAGEN Manchester Limited 16 Aug 2011

Advanced MRI techniques can identify early OA

Researchers from NYU Langone Medical Center's Departments of Orthopaedic Surgery and Radiology found that advanced MRI techniques can be used to detect subtle changes in joint cartilage microstructure - and provide physicians a diagnostic tool for finding key markers of early osteoarthritis.

16 Aug 2011

Novel assay can accurately detect prostate cancer than traditional screening

new prostate screening test developed by AnalizaDx, Inc., a Cleveland-based biotech company, and studied by researchers at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center along with colleagues at the Cleveland Clinic, the Veterans Administration Boston Healthcare and the National Cancer Institute, may prove to be a promising new tool in the diagnosis of prostate cancer.

16 Aug 2011

Britain’s hospital waits increase

According to the latest figures, the number of patients waiting more than four hours for treatment in accident and emergency departments has almost doubled in the space of a year. Figures show 161,422 patients were left waiting over four hours for major A&E treatment between April and June 2011 – 91% more than during the same period in 2010. A broader measure including minor injuries units and walk-in centres was also up 90%, to 165,279.

15 Aug 2011

Canon to display complete digital radiography solutions at AHRA 2011

Whether it is a radiography application for an emergency room (ER) or a neonatal intensive care unit, Canon U.S.A., Inc., a leader in digital imaging, offers various configurations to meet medical practitioners' needs. At the 2011 American Healthcare Radiology Administrators (AHRA) Exposition, Canon U.S.A. will display its complete digital radiography solutions at the Canon booth (#702) from August 14 -17.

12 Aug 2011

Alternatives needed to inaccurate blood tests used to diagnose active TB

A guest post in PLoS Medicine's "Speaking of Medicine" blog, written by tuberculosis (TB) researchers Madhukar Pai of McGill University, David Dowdy of the Johns Hopkins Bloomberg School of Public Health, and Karen Steingart of the University of Washington School of Public Health, examines the medical, public health and economic consequences of the widespread use of inaccurate antibody-based serological diagnostic tests for active TB.

12 Aug 2011

GEHC signs MOU with Concord Medical to form preferred strategic partnership in China

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it has signed an Memorandum of Understating with GE Healthcare, through its subsidiaries General Electric International Operations Company, Inc. and GE Medical Systems Trade & Development Co., Ltd., to form a preferred strategic partnership in China.

11 Aug 2011

Abbott launches new molecular assay to detect vector-borne microorganisms

Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis.

11 Aug 2011